Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...

Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

MRI showed more than 90% sensitivity in detecting nasopharyngeal carcinoma (NPC), surpassing endoscopy’s detection rate of 65.6% over a 5-year period. MRI particularly excelled in identifying ...

In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was associated ...

Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) patients’ tumours reveals distinct differences in tumour microenvironment of locoregionally advanced NPC, supporting the use of ...

Mark James, age 59, is a distance runner. One of his favorite races is the Blue Ridge Relay through the Blue Ridge Mountains of North Carolina, his home state. James grew up in rural eastern North ...

Barbara Burtness, MD, discusses the latest highlights from the AACR Annual Meeting 2026 that took place April 17-22.

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...

Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances, and Controversies Nasopharyngeal carcinoma (NPC) is a unique epithelial malignancy arising from the ...